Dynamite News Study discovers how protein is responsible for genetic inflammatory disease
A team of researchers revealed the significance of a particular protein complex in some types of immunological dysregulation. Read further on Dynamite News:
Cologne: A team of researchers revealed the significance of a particular protein complex in some types of immunological dysregulation.
Research led by Dr Hirotsugu Oda from the University of Cologne's CECAD Cluster of Excellence for Ageing Research and the findings could lead to novel therapeutic methods aimed at decreasing autoinflammation and'repairing' the immune systems of patients suffering from a hereditary malfunction of this protein complex. The study 'Biallelic human SHARPIN loss of function produces autoinflammation and immunodeficiency' was published in the journal Nature Immunology.
LUBAC, the linear ubiquitin assembly complex comprising the proteins HOIP, HOIL-1, and SHARPIN, has long been recognized for its critical role in maintaining immune homeostasis. Previous studies conducted on mouse models have elucidated the profound consequences of SHARPIN loss, leading to severe dermatitis due to excessive cell death of skin cells.
However, the specific implications of SHARPIN deficiency in human health have remained elusive until now.
Also Read |
Researchers find how important protein keeps cell membranes in balance
The research team reports for the first time on two human individuals with SHARPIN deficiency who exhibit symptoms of autoinflammation and immunodeficiency, but unexpectedly do not manifest dermatological issues as indicated by the relevant animal model. Upon further investigation, these individuals displayed a pathway that is crucial for immune response, the so-called compromised canonical NF-kB response.
They also showed increased susceptibility to cell death mediated by tumour necrosis factor (TNF) superfamily members. Treatment of one SHARPIN-deficient individual with anti-TNF therapies, which specifically suppress TNF-induced cell death, resulted in the complete resolution of autoinflammation at the cellular level and in clinical presentation.
The study shows that excessive and unchecked cell death plays a critical role in human genetic inflammatory diseases. Oda's team added SHARPIN deficiency as a novel member of human genetic inflammatory diseases, which they propose to name 'inborn errors of cell death'.
The study was initiated at Dr Dan Kastner's lab at the National Institutes of Health (NIH) in the USA. The scientists there had the opportunity to see one patient with childhood-onset unexplained fever episodes, arthritis, colitis and immunodeficiency. Upon obtaining informed consent, they performed exome sequencing of the patient and the family members and discovered that the patient had a deleterious genetic variant in the SHARPIN gene, leading to undetectable levels of SHARPIN protein.
Also Read |
New biomarker to diagnose Alzheimer's in asymptomatic stages
They further revealed that the patient cells show an increased propensity for cell death both in cell culture dishes and in patient biopsies. The team further observed that the development of lymphoid germinal centres - the specialized microstructures in adenoids which are critical for the maturation of the B cells of our immune system, and thus antibody production - was markedly diminished due to increased B cell death. These findings account for the immunodeficiency in patients and highlight the pivotal role of LUBAC in immune homeostasis in humans.
"Our research underscores the critical importance of LUBAC in safeguarding against immune dysregulation. By elucidating the molecular mechanisms underlying LUBAC deficiency, we pave the way for novel therapeutic strategies aimed at restoring immune homeostasis," said Oda, the lead author of the study.
He added, "One of the patients with SHARPIN deficiency had been dependent on a wheelchair for years before we first saw him. His ankles were inflamed, and it was too painful to walk. The genetic diagnosis enabled us to target the right molecular pathway underlying his conditions."
Since being placed on anti-TNF therapies, the patient has been symptom-free for almost seven years. "As both a clinician and a scientist, I am thrilled to have the opportunity to positively impact one patient's life through our research," Oda concluded. (ANI)